- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Metformin or lifestyle changes initiated for diabetes prevention may not reduce risk of AMD: JAMA
Age-related macular degeneration (AMD) is one of the most prevalent age-related eye conditions and a leading cause of blindness in the US. Early and intermediate stages of AMD can progress to 2 forms of late AMD: geographic atrophy and neovascular AMD. Hallmark features of early and intermediate AMD include drusen and pigment changes and are evaluated using various retinal imaging modalities. The natural history of AMD is progression from early AMD to the intermediate stage and eventual geographic atrophy and may be accompanied by the development of neovascular AMD.
The Diabetes Prevention Program Outcomes Study (DPPOS) is a follow-up phase of a large multicenter randomized clinical trial, Diabetes Prevention Program (DPP), to investigate the effects of treatment with metformin or an intensive lifestyle modification (lifestyle) compared with placebo on preventing the onset of type 2 diabetes in a population at high-risk of developing diabetes. As per the DPP protocol, eligibility criteria included age 25 years or older, a body mass index of 24 or higher, and a plasma glucose concentration of 95 to 125mg/dL in the fasting state and 140 to 199 mg/dL 2 hours after a 75-g oral glucose load. As part of an annual follow-up visit at year 16 of DPPOS, retinal images were acquired and AMD was evaluated. The DPPOS provides a unique opportunity to study the association of metformin and lifestyle changes with preventing or delaying the development of AMD.
The Diabetes Prevention Program Outcomes Study is a cross-sectional follow-up phase of a large multicenter randomized clinical trial, Diabetes Prevention Program (1996-2001), to investigate the association of treatment with metformin or an intensive lifestyle modification vs placebo with preventing the onset of type 2 diabetes in a population at high risk for developing diabetes. Participants with retinal imaging at a follow-up visit 16 years post trial were included. Analysis took place between October 2019 and May 2022. S Participants were randomly distributed between 3 interventional arms: lifestyle, metformin, and placebo.
Of 1592 participants, 514 (32.3%) were in the lifestyle arm, 549 (34.5%) were in the metformin arm, and 529 (33.2%) were in the placebo arm. AMD was identified in 479 participants (30.1%); 229 (14.4%) had early AMD, 218 (13.7%) had intermediate AMD, and 32 (2.0%) had advanced AMD. There was no significant difference in the presence of AMD between the 3 groups: 152 (29.6%) in the lifestyle arm, 165 (30.2%) in the metformin arm, and 162 (30.7%) in the placebo arm. There was also no difference in the distribution of early, intermediate, and advanced AMD between the intervention groups. Mean duration of metformin use was similar for those with and without AMD (P = .69). In the multivariate models, history of smoking was associated with increased risks of AMD (P = .02).
In the DPPOS, there was no difference in AMD presence or severity between metformin, intensive lifestyle intervention, and placebo arms at median time of 21 years since randomization. Using masked reading center interpretation of images, the DPPOS cohort is unique in its ability to examine the role of metformin in protecting against development of AMD due to both the randomization intervention arm and the duration of follow-up with known exposure to metformin. In addition, authors assessed associations of metformin use with AMD severity. Authors found no association of metformin use with the presence or severity of AMD, nor did they find an association between any use of metformin or number of years of metformin with AMD. Lastly, they found no association between in-study and out-of study metformin use and AMD.
To summarize, in the DPPOS cohort with 1592 participants randomized to metformin for over 20 years, there was no association between metformin use and prevalence of AMD. There was also no association with stages of AMD classified from multimodal imaging, nor was there an association with duration of metformin use. Until randomized data are available, the DPPOS provides strong evidence that does not support the use of metformin in the treatment of any stage of AMD.
Source: Amitha Domalpally, Samuel A. Whittier, Qing Pan; JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2022.5567
Dr Ishan Kataria has done his MBBS from Medical College Bijapur and MS in Ophthalmology from Dr Vasant Rao Pawar Medical College, Nasik. Post completing MD, he pursuid Anterior Segment Fellowship from Sankara Eye Hospital and worked as a competent phaco and anterior segment consultant surgeon in a trust hospital in Bathinda for 2 years.He is currently pursuing Fellowship in Vitreo-Retina at Dr Sohan Singh Eye hospital Amritsar and is actively involved in various research activities under the guidance of the faculty.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751